BeiGene opens European headquarters in Basel
BeiGene has opened its new European headquarters in Basel. The global biotech specializing in innovative cancer treatments intends to build on European growth out of Basel and its office will initially include 150 employees.
At the opening event: Christof Klöpper, CEO of Basel Area Business & Innovation, talks while John V. Oyler (seated far right), CEO of BeiGene, listens attentively (img: Annelise Michel)
Basel is joining Cambridge, Massachusetts, and Beijing, China, as a location of one of the main regional offices of BeiGene. According to a press release, the biotech’s European organization currently includes more than 270 employees. The Basel office will become a hub for BeiGene’s operations in Europe and initially employ 150 members of staff.
“The skilled talent network in Basel will support our future growth,” said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. And this is “just the beginning” of growth plans in Europe.
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. Its internal pipeline reportedly consists of 40 novel oral small molecules and monoclonal antibodies for cancer.
“Basel is the biotech hub of continental Europe“
At the opening event of BeiGene Switzerland GmbH, Deborah Strub, Member of the Executive Board and Head of the Cluster & Initiatives Department at the Chamber of Commerce of the two Basel cantons, said “BeiGene’s presence also represents a great opportunity for the Swiss and particularly the Basel economy”. Gerwin Winter, Head of Europe at BeiGene, commented “our new European headquarters in Basel will further strengthen our position and will be a catalyst for changing the lives of European patients.”
Christof Klöpper, CEO of Basel Area Business & Innovation, also welcomes the opening of the new offices. In an article in the Basler Zeitung newspaper he is quoted as saying “Basel is the biotech hub of continental Europe. In recent years we have worked hard to promote this message – to the USA and also China“.
Share this article
You may also be interested in
Noema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....Read More
Basel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...Read More
Ariceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...Read More
RocketVax raises fresh capital
The Basel-based biotech startup RocketVax has successfully closed another financing round. This additional funding will primarily be used to further...Read More
Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...Read More
KUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...Read More